Systemic diseases in myelodysplastic syndromes.

被引:18
|
作者
Hebbar, M
HebbarSavean, K
Fenaux, P
机构
来源
REVUE DE MEDECINE INTERNE | 1995年 / 16卷 / 12期
关键词
myelodysplastic syndrome; relapsing polychondritis; vasculitis; seronegative arthritis;
D O I
10.1016/0248-8663(96)80810-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myelodysplastic syndromes (MDS) are characterized by quantitative and functional involvement of myeloid lineages. Yet, systemic manifestations, suggestive of a lymphocytic involvement, have been described in MDS. We review here biological and clinical data concerning the associations between MDS and immunological disorders. Biological auto-immune markers are in fact rare in MDS, and especially encountered in the chronic myelomonocytic leukemia subgroup. Only a few systemic diseases seem to be frequently associated with MDS: seronegative arthritis, cutaneous vasculitis, and relapsing polychondritis. These diseases are probably not entirely auto-immune, and the signification of their association with an MDS remains nuclear. About 30% of relapsing polychondritis are associated with MDS. Conversely, 0.6% of MDS are associated with a relapsing polychondritis. These associations are mainly encountered in men suffering from a refractory anemia (with or without excess of blasts). The main cytogenetic abnormalities are monosomy 7, presence of a ring chromosome, and monosomy 16.
引用
收藏
页码:897 / 904
页数:8
相关论文
共 50 条
  • [21] Isolated Trisomy 8 in the Myelodysplastic Syndromes.
    Gangat, Naseema
    Greipp, Patricia
    Hanson, Curtis A.
    Hoyer, James
    Chen, Dong
    Ketterling, Rhett P.
    Dingli, David
    BLOOD, 2009, 114 (22) : 1089 - 1089
  • [22] Cutaneous manifestations associated with myelodysplastic syndromes.
    Morand, JJ
    Lightburn, E
    Richard, MA
    Hesse-Bonerandi, S
    Carsuzaa, F
    Grob, JJ
    REVUE DE MEDECINE INTERNE, 2001, 22 (09): : 845 - 853
  • [23] Myelodysplastic syndromes. Clinical and biological advances
    T Hamblin
    Bone Marrow Transplantation, 2006, 37 (8) : 809 - 809
  • [24] Pathogenesis of immunological abnormalities in myelodysplastic syndromes.
    Okamoto, T
    Okada, M
    Takemoto, Y
    Kanamaru, A
    Kakishita, E
    BLOOD, 1997, 90 (10) : 2316 - 2316
  • [25] Myelodysplastic syndromes. Incidence and survival in Republic of Armenia
    Daghbashyan, S.
    Sahakyan, L.
    Kabasakalyan, E.
    LEUKEMIA RESEARCH, 2013, 37 : S143 - S143
  • [26] Hypoalbuminemia Is An Independent Prognostic Factor In Myelodysplastic Syndromes.
    Corrales-Yepez, Maria
    Kharfan-Dabaja, Mohamed A.
    Lancet, Jeffrey
    List, Alan F.
    Padron, Eric
    Rollison, Dana
    Epling-Burnette, P. K.
    Zhang, Ling
    Field, Teressa
    Pinilla-Ibarz, Javier
    Komrokji, Rami S.
    BLOOD, 2010, 116 (21) : 1631 - 1631
  • [27] Concurrent inflammatory bowel disease and myelodysplastic syndromes.
    Harewood, GC
    Loftus, EV
    Sandborn, WJ
    Tremaine, WJ
    GASTROENTEROLOGY, 1998, 114 (04) : A991 - A991
  • [28] Myelodysplastic syndromes. Molecular background and clinical implications
    Mueller, N. Z.
    Hofmann, W. -K.
    Nolte, F.
    ONKOLOGE, 2012, 18 (12): : 1120 - 1129
  • [29] The immunophenotype and function of dendritic cells in myelodysplastic syndromes.
    Ling, M
    Delforge, M
    Verhoef, GEG
    Vandenberghe, PA
    BLOOD, 2002, 100 (11) : 166A - 167A
  • [30] Statins reduce mortality of patients with myelodysplastic syndromes.
    Afzal, Amber
    Fiala, Mark A.
    Jacoby, Meagan
    Walter, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)